Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: Exploratory analysis of the JCOG0303 study

Yasuo Hamamoto, Junki Mizusawa, Hiroshi Katayama, Kenichi Nakamura, Ken Kato, Yasuhiro Tsubosa, Satoshi Ishikura, Hiroyasu Igaki, Masayuki Shinoda, Haruhiko Fukuda, Yuukou Kitagawa, Nobutoshi Ando

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

It is important to examine variation in the treatment effects of patients with esophageal cancer in order to generalize treatment outcomes.We aimed to investigate the range of prognostic differences among hospitals in the treatment of locally advanced esophageal cancer. The JCOG0303 study compared the efficacy of radiotherapy plus low-dose cisplatin and 5-fluorouracil with that of high-dose cisplatin and 5-fluorouracil for unresectable esophageal cancer. Of 32 institutions participating in the JCOG0303 study, the 18 institutions that enrolled three or more patients were included in this study. We predicted the 1-year survival in each institution by using a mixed-effect model.We found that the predicted 1-year survival in the 18 institutions with three ormore patientswas amedian of 60.9%,with a range of 60.9-60.9%. This study is the first to investigated heterogeneity of survival in patients who received definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

Original languageEnglish
Pages (from-to)389-392
Number of pages4
JournalJapanese Journal of Clinical Oncology
Volume46
Issue number4
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Esophageal Neoplasms
Fluorouracil
Cisplatin
Survival
Chemoradiotherapy
Radiotherapy
Therapeutics

Keywords

  • Chemoradiotherapy
  • Esophageal cancer
  • Heterogeneity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer : Exploratory analysis of the JCOG0303 study. / Hamamoto, Yasuo; Mizusawa, Junki; Katayama, Hiroshi; Nakamura, Kenichi; Kato, Ken; Tsubosa, Yasuhiro; Ishikura, Satoshi; Igaki, Hiroyasu; Shinoda, Masayuki; Fukuda, Haruhiko; Kitagawa, Yuukou; Ando, Nobutoshi.

In: Japanese Journal of Clinical Oncology, Vol. 46, No. 4, 01.04.2016, p. 389-392.

Research output: Contribution to journalArticle

Hamamoto, Y, Mizusawa, J, Katayama, H, Nakamura, K, Kato, K, Tsubosa, Y, Ishikura, S, Igaki, H, Shinoda, M, Fukuda, H, Kitagawa, Y & Ando, N 2016, 'Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: Exploratory analysis of the JCOG0303 study', Japanese Journal of Clinical Oncology, vol. 46, no. 4, pp. 389-392. https://doi.org/10.1093/jjco/hyv211
Hamamoto, Yasuo ; Mizusawa, Junki ; Katayama, Hiroshi ; Nakamura, Kenichi ; Kato, Ken ; Tsubosa, Yasuhiro ; Ishikura, Satoshi ; Igaki, Hiroyasu ; Shinoda, Masayuki ; Fukuda, Haruhiko ; Kitagawa, Yuukou ; Ando, Nobutoshi. / Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer : Exploratory analysis of the JCOG0303 study. In: Japanese Journal of Clinical Oncology. 2016 ; Vol. 46, No. 4. pp. 389-392.
@article{a48ebca420d040dfb45199082ab25388,
title = "Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: Exploratory analysis of the JCOG0303 study",
abstract = "It is important to examine variation in the treatment effects of patients with esophageal cancer in order to generalize treatment outcomes.We aimed to investigate the range of prognostic differences among hospitals in the treatment of locally advanced esophageal cancer. The JCOG0303 study compared the efficacy of radiotherapy plus low-dose cisplatin and 5-fluorouracil with that of high-dose cisplatin and 5-fluorouracil for unresectable esophageal cancer. Of 32 institutions participating in the JCOG0303 study, the 18 institutions that enrolled three or more patients were included in this study. We predicted the 1-year survival in each institution by using a mixed-effect model.We found that the predicted 1-year survival in the 18 institutions with three ormore patientswas amedian of 60.9{\%},with a range of 60.9-60.9{\%}. This study is the first to investigated heterogeneity of survival in patients who received definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.",
keywords = "Chemoradiotherapy, Esophageal cancer, Heterogeneity",
author = "Yasuo Hamamoto and Junki Mizusawa and Hiroshi Katayama and Kenichi Nakamura and Ken Kato and Yasuhiro Tsubosa and Satoshi Ishikura and Hiroyasu Igaki and Masayuki Shinoda and Haruhiko Fukuda and Yuukou Kitagawa and Nobutoshi Ando",
year = "2016",
month = "4",
day = "1",
doi = "10.1093/jjco/hyv211",
language = "English",
volume = "46",
pages = "389--392",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer

T2 - Exploratory analysis of the JCOG0303 study

AU - Hamamoto, Yasuo

AU - Mizusawa, Junki

AU - Katayama, Hiroshi

AU - Nakamura, Kenichi

AU - Kato, Ken

AU - Tsubosa, Yasuhiro

AU - Ishikura, Satoshi

AU - Igaki, Hiroyasu

AU - Shinoda, Masayuki

AU - Fukuda, Haruhiko

AU - Kitagawa, Yuukou

AU - Ando, Nobutoshi

PY - 2016/4/1

Y1 - 2016/4/1

N2 - It is important to examine variation in the treatment effects of patients with esophageal cancer in order to generalize treatment outcomes.We aimed to investigate the range of prognostic differences among hospitals in the treatment of locally advanced esophageal cancer. The JCOG0303 study compared the efficacy of radiotherapy plus low-dose cisplatin and 5-fluorouracil with that of high-dose cisplatin and 5-fluorouracil for unresectable esophageal cancer. Of 32 institutions participating in the JCOG0303 study, the 18 institutions that enrolled three or more patients were included in this study. We predicted the 1-year survival in each institution by using a mixed-effect model.We found that the predicted 1-year survival in the 18 institutions with three ormore patientswas amedian of 60.9%,with a range of 60.9-60.9%. This study is the first to investigated heterogeneity of survival in patients who received definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

AB - It is important to examine variation in the treatment effects of patients with esophageal cancer in order to generalize treatment outcomes.We aimed to investigate the range of prognostic differences among hospitals in the treatment of locally advanced esophageal cancer. The JCOG0303 study compared the efficacy of radiotherapy plus low-dose cisplatin and 5-fluorouracil with that of high-dose cisplatin and 5-fluorouracil for unresectable esophageal cancer. Of 32 institutions participating in the JCOG0303 study, the 18 institutions that enrolled three or more patients were included in this study. We predicted the 1-year survival in each institution by using a mixed-effect model.We found that the predicted 1-year survival in the 18 institutions with three ormore patientswas amedian of 60.9%,with a range of 60.9-60.9%. This study is the first to investigated heterogeneity of survival in patients who received definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

KW - Chemoradiotherapy

KW - Esophageal cancer

KW - Heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=84965052563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965052563&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyv211

DO - 10.1093/jjco/hyv211

M3 - Article

C2 - 26830150

AN - SCOPUS:84965052563

VL - 46

SP - 389

EP - 392

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 4

ER -